Type 4 phosphodiesterase plays different integrating roles in different cellular domains in pyramidal cortical neurons

J Neurosci. 2010 Apr 28;30(17):6143-51. doi: 10.1523/JNEUROSCI.5851-09.2010.

Abstract

We investigated the role of phosphodiesterases (PDEs) in the integration of cAMP signals and protein kinase A (PKA) activity following beta-adrenergic stimulation, by carrying out real-time imaging of male mouse pyramidal cortical neurons expressing biosensors to monitor cAMP levels (Epac1-camps and Epac2-camps300) or PKA activity (AKAR2). In the soma, isoproterenol (ISO) increased the PKA signal to approximately half the maximal response obtained with forskolin, with a characteristic beta(1) pharmacology and an EC(50) of 4.5 nm. This response was related to free cAMP levels in the submicromolar range. The specific type 4 PDE (PDE4) inhibitor rolipram had a very small effect alone, but strongly potentiated the PKA response to ISO. Blockers of other PDEs had no effect. PDE4 thus acts as a brake in the propagation of the beta(1)-adrenergic signal from the membrane to the bulk somatic cytosol. The results for a submembrane domain were markedly different, whether recorded with a PKA-sensitive potassium current related to the slow AHP or by two-photon imaging of small distal dendrites. The responses to ISO were stronger than in the bulk cytosol. This is consistent with the cAMP/PKA signal being strong at the membrane, as shown by electrophysiology, and favored in cellular domains with a high surface area to volume ratio, in which this signal was detected by imaging. Rolipram alone also produced a strong cAMP/PKA signal, revealing tonic cAMP production. PDE4 thus appears as a crucial integrator with different physiological implications in different subcellular domains.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-Agonists / pharmacology
  • Animals
  • Cell Membrane / drug effects
  • Cell Membrane / enzymology
  • Cell Membrane / metabolism
  • Central Nervous System Agents / pharmacology
  • Colforsin / pharmacology
  • Cyclic AMP / metabolism
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / metabolism*
  • Dendrites / drug effects
  • Dendrites / enzymology
  • Dendrites / metabolism
  • In Vitro Techniques
  • Isoproterenol / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Parietal Lobe / drug effects
  • Parietal Lobe / enzymology*
  • Parietal Lobe / metabolism
  • Phosphodiesterase 4 Inhibitors
  • Phosphodiesterase Inhibitors / pharmacology
  • Potassium / metabolism
  • Pyramidal Cells / drug effects
  • Pyramidal Cells / enzymology*
  • Pyramidal Cells / metabolism
  • Receptors, Adrenergic, beta-1 / metabolism
  • Rolipram / pharmacology

Substances

  • Adrenergic beta-1 Receptor Agonists
  • Adrenergic beta-Agonists
  • Central Nervous System Agents
  • Phosphodiesterase 4 Inhibitors
  • Phosphodiesterase Inhibitors
  • Receptors, Adrenergic, beta-1
  • Colforsin
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Adenylyl Cyclases
  • Rolipram
  • Isoproterenol
  • Potassium